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Background: Secreted frizzled-related proteins (SFRP) are regulators of Wnt-signalling. SFRP4 has been shown to
regulate insulin exocytosis and is overexpressed in type 2 diabetes mellitus.
Here we characterized the relation of SFRP4 to glucose and triglyceride metabolism and outcomes in patients with
stable coronary artery disease on statin treatment in the prospective Homburg Cream & Sugar Study
(NCT00628524).
Methods: Fasting SFRP4 concentrations were measured by ELISA in 504 consecutive patients with stable CAD
confirmed by angiography.
Results: The median age was 68 years and 83% of patients were male. Oral glucose tolerance tests were performed
in all patients without known diabetes for metabolic characterization. 24.4% of patients showed normal glucose
tolerance, 29.4% impaired glucose tolerance and 46.2% diabetes mellitus. SFRP4 concentrations correlated with
insulin (R = 0.153, p = 0.001), HbA1c (R = 0.166, p < 0.0001), fasting triglycerides (R = 0.113, p = 0.011) and higher
triglycerides after lipid challenge (postprandial triglycerides R = 0.124, p = 0.005; AUC R = 0.134, p = 0.003). Higher
SFRP4 concentrations were associated with type 2 diabetes, metabolic syndrome, and severity of diabetes.
The primary outcome was the composite of cardiovascular death and cardiovascular hospitalization within
48 months follow-up. Comparison of event-free survival between SFRP4 tertiles showed that SFRP4 concentrations
were not predictive for cardiovascular outcome.
Conclusions: SFRP4 concentrations are associated with impaired glucose and triglyceride metabolism but do not
predict cardiovascular outcome in patients with stable coronary artery disease on treatment.
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Type 2 diabetes (T2DM) is a chronic, progressive disease
characterized by insulin resistance and beta-cell dysfunction
resulting in the decline of insulin production and secretion.
T2DM is contributing to a significant morbidity and mor-
tality, it affects more than 300 million individuals world-
wide and the prevalence is still increasing, with the
expectation of 439 million adults affected by 2030 [1].
Wnt (Wingless and Int-1) signalling is a conserved path-
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unless otherwise stated.of adult tissue and in carcinogenesis [2,3]. Several Wnt
pathway components are associated with lipid and glucose
metabolism and thereby influence the development of dia-
betes. Variations in the Wnt co-receptors LRP5 and LRP6
are associated with type 1 diabetes [4] and early coronary
disease and the metabolic syndrome [5]. TCF7L2, a tran-
scription factor at the end of the Wnt-signalling cascade is
the most prominent hit in genome-wide association studies
exploring the genetics of T2DM [6]. TCF7L2 might be a
key regulator of proinsulin synthesis, processing and pos-
sibly clearance [7] and is involved in the regulation of incre-
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ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Hoffmann et al. Cardiovascular Diabetology 2014, 13:155 Page 2 of 8
http://www.cardiab.com/content/13/1/155Wnt-signalling is modulated at several levels. A number
of secreted proteins, including secreted frizzled-related
proteins (SFRPs), bind Wnts, thereby modulating their ac-
tion [2]. SFRPs share homology with the extracellular do-
main of frizzled proteins but lack the transmembrane and
intracellular components that are necessary for signalling
transduction. SFRPs antagonize Wnt-signalling by competi-
tively binding to Wnts or to their receptors in the plasma
membrane. In humans, the SFRP family consists of 5 mem-
bers, termed SFRP1-5. Several SFRPs have been described as
adipokines with different roles in adipogenesis [9-11] and
SFRP4 as a regulator of insulin exocytosis in murine and hu-
man islet cells [12]. Moreover, the authors presented data
showing an association of SFRP4 serum levels with insulin
resistance and T2DM. Interestingly, in two small cohorts
SFRP4 was elevated several years before clinical diagnosis of
diabetes, assuming the possibility of SFRP4 as an early dia-
betes marker [12].
Another SFRP, which has been associated with type 2 dia-
betes, is SFRP5. However, the role of SFRP5 in type 2 diabetes
is still controversial. Three studies describe an association
of higher SFRP5 levels with type 2 diabetes [13,14] or insulin
resistance in non-diabetic subjects [15], whereas two studies
show the opposite effect, lower SFRP5 levels in subjects
with prediabetes or type 2 diabetes in comparison to controls
[16,17].
To assess the above described association of SFRP4
serum levels with insulin resistance and T2DM we ana-
lysed SFRP4 in 504 patients with clinically stable coron-
ary artery disease from the prospective observational
Homburg Cream and Sugar study [18]. The strength of
the Homburg Cream & Sugar Study is the detailed clinical
and metabolic characterisation of the patients, including a




Methods of the Homburg Cream and Sugar study
(NCT00628524) have been described in detail [18]
elsewhere. Briefly, from February 2008 to July 2009,
504 consecutive patients with clinically stable coron-
ary artery disease (CAD) documented by angiography
were enrolled in this prospective, observational study.
Institutional approval was provided by the ethics com-
mittee of the Saarland (number 170/07) and all partic-
ipants gave written informed consent.
Metabolic syndrome, impaired glucose tolerance and
diabetes were defined according to current recommen-
dations [19,20]: The metabolic syndrome was considered
when three of the following criteria were positive: elevated
waist circumference (men ≥94 cm, women ≥80 cm), ele-
vated fasting TG (≥150 mg/dl), low HDL-cholesterol
(men <40 mg/dl, women <50 mg/dl), elevated fastingglucose (≥110 mg/dl or drug treatment for diabetes) or el-
evated blood pressure (≥140 mmHg systolic or ≥90 mmHg
diastolic treatment naïve or on anti-hypertensive treat-
ment). Type 2 diabetes was defined based on validated
physician diagnosis and newly diagnosed diabetes accord-
ing to the guidelines of the American Diabetes Association
when fasting glucose was ≥126 mg/dl, HbA1c >6.5% and/
or 2-hour glucose was ≥200 mg/l. Laboratory measure-
ments were performed at the core facilities of the Medical
University of the Saarland.
Follow-up data were obtained by standardized telephone
interviews after 12, 24, and 48 months. The primary out-
come was the composite of cardiovascular death and cardio-
vascular hospitalisation for acute coronary syndrome (for
definitions see [21,22]) or hospitalization for unplanned,
symptom-induced coronary angiography and revasculariza-
tion including bypass surgery.
SFRP4 assay
Fasting SFRP4 concentrations were measured in duplicate
by an enzyme-linked immunosorbent assay produced by
Phadia GmbH (Freiburg, Germany) in diluted (1:11) fasting
serum samples according to the manufacturer’s instructions.
A 4–point standard curve (0,0 – 0,2 – 1,0 – 5,0 ng/ml) was
created using lyophilized recombinant human SFRP4. Sam-
ples that were out of the range of the standard curve were
further diluted (1:5) and measured again. Intra-assay and
inter-assay variations were 6.8% and 9.1%, respectively.
Statistical analysis
Kolmogorov–Smirnov tests showed that continuous base-
line variables were not normally distributed in the cohort.
Data are there foreshown as median and interquartile
(25%-75%) range (Table 1). SFRP4 serum concentrations
were not evenly distributed; therefore, log(SFRP4) was used
for all analyses. Patients were stratified by log(SFRP4) ter-
tiles to analyse differences in baseline characteristics using
ANOVA for continuous and Fisher’s exact tests for categor-
ical variables (Table 2). Furthermore, log(SFRP4) concentra-
tions were compared with continuous variables by two-
sided Pearson correlation and linear regression analyses
and between strata of categorical variables by Spearman’s
rank correlation (Tables 3 and 4). The number of endpoints
between log(SFRP4) tertiles was compared in cross-tables
using Chi2 tests (Table 5) and time-to-event analyses were
performed with Kaplan-Meier-Curves using log-rank tests
(Figure 1) and univariate Cox proportional regression ana-
lyses to calculate hazard ratios (HR) and 95% confidence in-
tervals (95%-CI). To this end, the lower log(SFRP4) tertile
was set as reference category (HR 1.0) and the upper tertile
as the comparator (Table 6).
The null hypothesis was rejected and statistical signifi-
cance was assumed at p-values <0.05. All statistical analyses
were performed with SPSS software version 20.0.




Age (years) 68 (59, 74)
Male 83.3 (420)
Clinical characteristics
Smoking (active) 18.8 (99)
Alcohol regularly 23.8 (120)
Positive family history 31 (156)
Hyperlipidemia 86.3 (435)
Diabetes mellitus (treated) 32.7 (165)
Arterial hypertension 92.7 (467)
Systolic blood pressure (mm Hg) 125 (120, 140)
Diastolic blood pressure (mm Hg) 80 (70, 80)
Body mass index (kg/m2) 28 (26, 31)
Waist circumference (cm) 102 (73, 139)
Waist-to-hip ratio 1.0 (0.96, 1.05)
Metabolic characterization
Normal glucose tolerance 24.4 (123)
Impaired glucose tolerance 28.4 (143)
Diabetes mellitus (treated & newly
diagnosed)
47.2 (238)
Metabolic syndrome 64.9 (327)
Fasting glucose (mg/dl) 110 (101, 132)
HOMA index (mg/dl*μIU/ml) 2.3 (1.3, 4.1)
HbA1c (%)* 5.8 (5.5, 6.5)
Total cholesterol (mg/dl) 167 (143, 199)
HDL cholesterol (mg/dl) 43 (35, 53)
LDL cholesterol (mg/dl) 100 (80, 129)
Fasting triglycerides (mg/dl) 126 (96, 175)
Postprandial triglycerides, maximum (mg/dl) 237 (175, 347)
Postprandial triglycerides, AUC (mg/dl) 905 (665, 1278)
C-reactive protein (mg/l) 2.2 (0.9, 4.9)
SFRP4 (μg/l) 11.21 (9.17, 13.86)
Categorical variables are shown as rate (number). Plus-minus values are
depicted as median (interquartile range). Active smoking was regular tobacco
use at or within 12 months prior to enrolment. Regular alcohol use was
consumption of any alcoholic beverage >3 times/week. The HOMA
(Homeostasis Model Assessment) index is the fasting glucose concentration
(in milligrams per deciliter) multiplied by the fasting insulin concentration
(in microunits per milliliter) divided by 405.
*HbA1c was missing in 23 patients.
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For this study N = 504 patients with angiographically
confirmed stable CAD were enrolled. The median age
was 68 years and 83% of the patients were male. 32.7%
of the patients had a history of T2DM, after oral glucose
tolerance test 13.5% (N = 68) were newly diagnosed for
T2DM and an impaired glucose tolerance was seen in29.4%, thus in this cohort only 24.4% of the patients showed
a normal glucose tolerance (Table 1). SFRP4 serum levels
were in the range of 3.64 – 41.2 μg/l, with a median of
11.21 μg/l. SFRP4 serum concentrations were not evenly
distributed (Kolmogorov-Smirnov-Z 4.854, p <0.001); there-
fore we used (log)SFRP4 for the following analysis.
The patient characteristics in the SFRP4 tertiles are
displayed in Table 2 and Figure 1. Patients in the highest
SFRP4 tertile were older and more often had a history of
myocardial infarction, percutaneous intervention or by-
pass operation. Waist circumference and BMI were in-
creasing significantly from the lowest to the highest
tertile. Patients in the first tertile showed significantly
lower levels of fasting insulin, HbA1c, fasting and post-
prandial triglycerides and in accordance to this the frac-
tion of patients with T2DM or metabolic syndrome in
the first tertile was considerably lower in comparison to
the other tertiles. In correlation analyses (Table 3) SFRP4
concentrations correlated with HbA1c, fasting insulin,
BMI, fasting and postprandial triglycerides. Comparison
of SFRP4 concentrations between strata of categorical
variables showed that SFRP4 levels were higher in pa-
tients with metabolic syndrome, insulin therapy, diabetes
and a history of myocardial infarction or PCI (Table 4).
Within 4 years follow-up 287 patients survived event-free
and 217 patients experienced a primary cardiovascular end-
point such as acute coronary syndromes, major adverse
cardiovascular events and cardiovascular death + non-fatal
myocardial infarction. Interestingly, the number of patients
experiencing a stroke/transitory ischemic attack (TIA) was
significantly higher in the upper SFRP4 tertile, both in
descriptive as well as in univariate time-to-event ana-
lyses (Tables 5 and 6). However, the association of
sFPR4 was not independent of other risk factors, be-
cause significance was rapidly lost upon multivariable
adjustment (not shown).
Discussion
The importance and burden of T2DM for our health
system is permanently increasing, despite all efforts in
primary prevention. Because it is a progressive disease
which does not cause specific symptoms for many years
diagnosis at an early state is of outmost importance.
Usually, the diagnosis starts with measurement of fasting
plasma glucose or HbA1c, the advantages and disadvan-
tages of HbA1c measurement are discussed in a WHO
report from 2011 [23]. Oral glucose tolerance test is still
the gold standard but due to the time consuming pro-
cedure not feasible everywhere. With the help of the
OGTT we were able to detect 68 (13.5%) previously un-
known patients with diabetes in the HCS study, support-
ing the observation of a high estimated number of
unreported cases in secondary prevention cohorts and
the general population [24].
Table 2 Baseline characteristics, stratified by tertiles of (log)SFRP4
(log) SFRP4 Tertiles
1 2 3
(log)SFRP4 range <0.99 0.99 – 1.11 >1.11 p-Value
Group size 33.3 (168) 33.3 (168) 33.3 (168)
Age (years) 65.2 ± 0.7 65.8 ± 0.8 68.2 ± 0.8 0.017
Male 86.3 (145) 85.7 (144) 78.0 (131) 0.068
Medical history
Previous myocardial infarction 35.7 (60) 44.6 (75) 51.8 (87) 0.014
PCI 57.1 (96) 66.7 (112) 76.8 (129) 0.001
Bypass operation 7.1 (12) 14.3 (24) 16.1 (27) 0.03
Previous stroke or TIA 6.0 (10) 12.5 (21) 13.1 (22) 0.065
Peripheral artery disease 6.5 (11) 10.1 (17) 10.7 (18) 0.37
Clinical characteristics
Smoking 21.4 (36) 20.8 (35) 14.3 (24) 0.18
Alcohol regularly 27.4 (46) 25.0 (42) 19.0 (32) 0.18
Positive family history 31.5 (53) 29.2 (49) 32.1 (54) 0.79
Arterial hypertension 88.7 (149) 94.0 (158) 95.2 (160) 0.095
Systolic BP (mmHg) 124.3 ± 1.2 127.0 ± 1.2 128.2 ± 1.3 0.067
Diastolic BP (mmHg) 74.0 ± 0.7 74.9 ± 0.7 74.8 ± 0.8 0.62
BMI (kg/m2) 27.9 ± 0.3 29.4 ± 0.3 29.3 ± 0.4 0.002
Waist circumference (cm) 100.9 ± 0.8 104.9 ± 0.9 104.9 ± 0.9 0.001
Waist-to-hip-ratio 1.00 ± 0.0 1.00 ± 0.0 1.01 ± 0.0 0.36
Metabolic characterization
Normal glucose tolerance 32.1 (54) 20.2 (34) 20.8 (35) 0.017
Impaired glucose tolerance 29.8 (50) 28.6 (48) 26.8 (45) 0.84
Diabetes mellitus 38.1 (64) 51.2 (86) 52.4 (88) 0.014
Metabolic syndrome 50.6 (85) 72.0 (121) 72.0 (121) <0.0001
Fasting glucose (mg/dl) 118.6 ± 2.5 119.5 ± 2.3 125.0 ± 2.6 0.15
Fasting insulin (μIU/ml) 8.73 ± 0.6 11.41 ± 0.9 12.69 ± 1.1 0.007
HOMA index 2.70 ± 0.24 3.64 ± 0.36 4.33 ± 0.55 0.018
HbA1c (%)* 6.05 ± 0.1 6.09 ± 0.1 6.40 ± 0.1 0.011
Total cholesterol (mg/dl) 175.0 ± 2.8 171.2 ± 3.2 170.9 ± 3.0 0.55
HDL cholesterol (mg/dl) 46.5 ± 1.0 43.8 ± 1.0 43.8 ± 1.1 0.12
LDL cholesterol (mg/dl) 107.7 ± 2.4 105.3 ± 2.8 101.0 ± 2.6 0.19
Fasting triglycerides (mg/dl) 133.9 ± 5.3 164.6 ± 15.0 170.0 ± 9.9 0.043
Postprandial triglyerides, maximum (mg/dl) 253.5 ± 9.7 305.4 ± 19.7 309.9 ± 14.2 0.015
Postprandial triglycerides, AUC (mg/dl) 943.8 ± 36.2 1135.6 ± 68.5 1160.3 ± 54.4 0.010
C-reactive protein (mg/l) 3.65 ± 0.5 4.90 ± 0.5 4.99 ± 0.7 0.16
Categorical variables are shown as rate (number) and continuous values as mean (SEM). TIA denotes transitory ischemic attack. Active smoking was regular
tobacco use at or within 12 months prior to enrolment. Regular alcohol use was consumption of any alcoholic beverage >3 times/week. The HOMA (Homeostasis
Model Assessment) index is the fasting glucose concentration (in milligrams per deciliter) multiplied by the fasting insulin concentration
(in microunits per milliliter) divided by 405.
*HbA1c was missing in 23 patients.
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impaired glucose metabolism are missing, except post-
prandial plasma glucose. Thus, a recent publication of
Mahdi et al. [12] attracted a great deal of attention,cumulating in the title “Mining Genes in Type 2 Dia-
betic Islets and Finding Gold” of an accompanying edi-
torial [25] and in a computer aided screening for SFRP4
inhibitors [26]. In a set of elegant experiments Mahdi
Table 3 Correlation of (log)SFRP4 concentration with
baseline characteristics
Parameter Pearson R p-Value
HbA1c 0.17 <0.0001
Fasting insulin 0.15 0.001
Body mass index 0.15 0.001
Fasting triglycerides 0.11 0.011
Postprandial triglycerides 0.12 0.005
Postprandial triglycerides AUC 0.13 0.003
Age 0.09 0.053
Continuous baseline variables were compared with (log)SFRP4 concentrations
by two-sided Pearson correlation; no significant association between SFRP4
and other than the listed was seen.
Table 5 Number of events, stratified by (log)SFRP4
tertiles
(log)SFRP4 tertiles
<0.99 0.99 – 1.11 >1.11 p-Value
N = 168 N = 168 N = 168
Event number per tertile
All primary
endpoints
72 69 76 0.74
Acute coronary
syndrome
16 15 26 0.11
MACE* 45 40 42 0.82
Stroke/TIA 8 10 19 0.049
Cardiovascular
death + non-fatal MI
16 20 16 0.71
All-cause death 9 16 18 0.18
Descriptive statistics (Chi2) were used to compare the number of patients with
events between (log)SFRP4 tertiles.
*MACE =Major adverse cardiovascular events (Combination of myocardial
infarction, unplanned revascularization and cardiovascular death).
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in vitro in mouse and human islets and in vivo in
SFRP4-treated mice. The reduced secretion was ex-
plained by decreased expression of L-type and P/Q-type
Ca2+ channels in the islets’ cells causing a suppression
of insulin exocytosis. This corresponds well to previous
published data of Taneera et al. [27], describing aTable 4 Correlation of (log)SFRP4 concentration with
baseline characteristics
Characteristic No. Log(SRFP4) Spearman’s Rho p-Value
Mean ± SEM
Previous myocardial infarction 0.13 0.007
No 282 1.04 ± 0.1
Yes 222 1.08 ± 0.1
Previous PCI 0.17 0.001
No 167 1.03 ± 0.1
Yes 337 1.07 ± 0.1
Previous cardiac bypass operation 0.13 0.005
No 441 1.05 ± 0.1
Yes 63 1.10 ± 0.1
Previous stroke 0.11 0.026
No 451 1.05 ± 0.1
Yes 53 1.10 ± 0.2
T2DM 0.11 0.011
No 266 1.04 ± 0.1
Yes 238 1.07 ± 0.1
Insulin therapy 0.17 0.001
No 429 1.05 ± 0.1
Yes 75 1.10 ± 0.2
Metabolic syndrome 0.16 <0.0001
No 177 1.02 ± 0.1
Yes 327 1.08 ± 0.1
Mean (log)SFRP4 concentrations were compared between strata of categorical
variables by Spearman’s rank correlation test; no association between SFRP4
and parameters other than the listed.significant inverse correlation of SFRP4 expression in
human pancreatic islets with insulin secretion (R = −0.28;
p = 0.03). This was supported by in vitro experiments with
isolated human pancreatic islets showing that recombin-
ant SFRP4 inhibits insulin secretion by 30% and cell exo-
cytosis by 50%. Besides the functional characterization of
SFRP4 action in islets Mahdi et al. reported a significant
correlation of serum SFRP4 concentration with fasting
glucose (β = 0.142; p = 0.004), reduced insulin sensitivity
index (β = −0.176; p = 0.002) and lower disposition
index (insulin secretion adjusted for insulin sensitivity;
β = −0.186; p = 0.029) in non-diabetic subjects [12]. Fur-
thermore they described elevated SFRP4 serum levels
several years before the clinical diagnosis of T2DM was
made, proposing the possibility of SFRP4 as an early
risk predictor [12].
In the HCS study we could confirm their observation
that T2DM patients are characterized by higher SFRP4
levels. Looking at specific parameters of the glucose me-
tabolism in the HCS study we found for fasting glucose
only an insignificant trend towards higher levels in the
second and third tertile, whereas we observed a signifi-
cant positive correlation of SFRP4 serum levels with fast-
ing insulin and HbA1c, a more reliable glucose sensor
than fasting glucose. This observation is in part sup-
ported by Taneera et al. who described a strong correl-
ation of SFRP4 expression in isolated islet cells with
HbA1c levels of the donors [27]. On the other hand at
the moment it is not clear to which extend SFRP4 pro-
duction in islets corresponds to SFRP4 serum levels or
vice versa.
We not only observe an association of higher SFRP4
concentrations with T2DM but also with the metabolic
syndrome. SFRP4 was associated with higher BMI, waist
A Type 2 diabetes mellitus B    Metabolic Syndrome
C BMI
Figure 1 Incidence of metabolic conditions within (log)SFRP4 tertiles. (A) Incidence of T2DM within (log)SFRP4 tertiles. (B) Incidence of
metabolic syndrome within (log)SFRP4 tertiles. (C) Incidence of different BMI classes (<30, 30-35, 35-40, >40) within (log)SFRP4 tertiles.
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prandial after a standardized lipid challenge), all attri-
butes of the metabolic syndrome. Recently, it has been
shown that SFRP4 is an adipokine [11]. The expression
of SFRP4 is up-regulated in human visceral white adi-
pose tissue of obese subjects and correlates with in-
creased insulin resistance. There is some evidence that
SFRP4 might influence the secretion of adiponectin
from adipocytes [11]. SFRP4 is also involved in adipo-
genesis [9]. Park et al. showed that the expression ofTable 6 Number of events, stratified by (log)SFRP4 tertiles
HR 95%-CI p-Value
All primary endpoints 1.05 0.76 - 1.45 0.77
Acute coronary syndrome 1.65 0.89 – 3.08 0.12
MACE* 0.91 0.60 – 1.38 0.64
Stroke/TIA 2.45 1.07 – 5.59 0.034
Cardiovascular death + non-fatal MI 0.99 0.50 – 1.99 0.99
All-cause death 2.02 0.91 – 4.50 0.084
Univariate cox proportional hazards regression analyses were used to compare
time to events between (log)SFRP4 tertiles. Hazard ratios (HR) and 95%
confidence intervals (95%-CI) are provided for the comparison of the third
tertile vs. the first tertile (reference category, HR =1.0).
*MACE =Major adverse cardiovascular events (Combination of myocardial
infarction, unplanned revascularization and cardiovascular death).SFRP4 is increased during the adipogenic differentiation
of human adipose tissue-derived mesenchymal stem
cells and that transfection with siSFRP4 reduced the de-
gree of adipocytic differentiation.
A trigger for the increased expression of SFRP4 in dia-
betes can be methylglyoxal. Methylglyoxal (MG), also
called pyruvaldehyde or 2-oxopropanal, is formed by the
degradation of the glycolytic intermediates, dihydroxyacet-
one phosphate, and glyceraldehyde-3-phosphate [28]. MG
reacts with free amino groups of lysine and arginine and
with thiol groups of cysteine, forming advanced glycation
endproducts. MG concentrations are highly increased in
diabetes and are associated with the development of diabetic
complications, as demonstrated in several studies [29-32].
Recently, Mori et al. [33] could show that MG can increase
SFRP4 gene expression 4-fold in ST2 cells, a mouse bone
marrow stromal cell-line. This increase was achieved by an
epigenetic derepression of the SFRP4 gene.
Studies describing SFRP4 levels in blood are rare; most
groups analyzed SFRP4 on the cellular level or within
tumor tissues, supporting the function of SFRP4 as
tumor suppressor gene [3]. Besides the study of Madhi
et al. [12] and the here presented HCS study only three
other groups published SFRP4 serum or plasma levels
[34-36]. Berndt et al. described for serum a range of
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et al. published for serum a mean of 28.5 ± 1.7 ng/ml for
24 unaffected controls and 38.1 ± 2.3 ng/ml for patients
with high bone mass causing mutations in LRP5 [36].
Jacob et al. were interested in the role of SFRP4 in ovarian
cancer and next to SFRP4 expression levels in tumors
and cell-lines they published SFRP4 plasma levels which
are about 100-fold higher than in the other studies. This
discrepancy underlines the need for standardized assays
for the necessary studies to further evaluate the role of
SFRP4 in diabetes. Besides, the study of Jacob et al. shows
that the interpretation of SFRP4 levels demand a detailed
evaluation of the patients: In patients with ovarian cancer
the reduction in SFRP4 levels could cover the increase
associated with the development of diabetes whereas in
diabetic patients the increased SFRP4 levels could interfere
with the effort to predict the outcome of a newly diag-
nosed tumor. Due to the exclusion criteria of the HCS
study we can be sure that our results were not compro-
mised by cancer.
Within 4 years follow-up nearly half of the patients expe-
rienced a primary cardiovascular endpoint. The association
of higher SFRP4 concentrations with stroke/TIA seems to
be a hit by chance since significance was rapidly lost upon
multivariable adjustment.
Limitations
During follow-up we obtained no fresh blood samples to
diagnose the onset of T2DM or a change in SFRP4 concen-
tration. The number of patients with a new onset of T2DM
during follow-up was too small for reliable statistical ana-
lysis of this parameter.
Conclusions
This prospective study shows that higher SFRP4 concentra-
tions are associated with T2DM and the metabolic syn-
drome in well-treated patients with coronary artery disease.
SFRP4 concentrations are a novel marker of impaired glu-
cose and triglyceride metabolism, but do not predict cardio-
vascular outcome in patients with stable coronary artery
disease.
Further research is necessary to elucidate the relevance
of SFRP4 levels in healthy people and patients with cardio-
vascular disease and its prognostic value for diabetes and
cancer.
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